The NGX System – an Advancement in Precision Medicine for Radiotherapy of the Skin

Since Roentgen’s discovery in 1895, X-rays have been used for diagnosis and treatment.
Today, approximately 50% of all the cancer patients undergo some form of radiotherapy.
The use of radiotherapy is particularly effective for the treatment of skin cancer, the
prevalence of which has increased dramatically over the past decade, with one in every three
cancers now diagnosed as a skin cancer.
For the treatment of cancers at or close to the skin Superficial X-Ray Therapy (SXT) and
Orthovoltage radiotherapy (DXT) are common treatment options utilizing low energy ionizing
radiation to treat cancer. The shallow penetrating power of both SXT and DXT means that
they often provide superior dose distributions compared to other techniques for the treatment
of superficial lesions as well as the treatment of non -malignant skin conditions, an emerging
treatment market that includes conditions such as keloids, plantar fasciitis and psoriasis.
With the number of new skin cancer cases diagnosed, projected to increase to more than 21
million by 2030 globally, and with clinical demand for radiotherapy already outstripping
supply, ensuring access to effective treatment is a key public health issue.
Xstrahl, an established supplier of X ray therapy solutions, aim to address this market need
through the development of new generation advanced lightweight, portable X ray therapy
system (NGX), capable of meeting the demands of the majority of oncological superficial
therapy and benign condition treatment plans. NGX will allow for accurate, patient specific
treatment through the integration of a unique in-beam dosimetry system that will measure
dosage delivery on the skin itself with the capability to adjust exposure accordingly with a
high level of safety and reduced treatment time. Its ergonomic design will allow for greater
patient comfort with portable capabilities therefore allowing treatment outside of a hospital
providing a high level of patient access.